A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
A phase 1/2 trial of Ipilimumab, Nivolumab in metastatic cancer and melanoma, run by 7 Hills Pharma, LLC, now recruiting.
Overview
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy is a phase 1/2 interventional study registered as NCT06362369 by 7 Hills Pharma, LLC, with 126 participants planned, started 2024-08-23 and due to reach its primary completion in 2027-12-31. Interventions recorded: Alintegimod, Ipilimumab, Nivolumab. Conditions listed: Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.
- TrialStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Shares Ipilimumab, Nivolumab, Metastatic cancer (cancer that has spread).
- TrialGM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Shares Renal cell carcinoma, Melanoma, Colorectal cancer.
- TrialMEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Shares Ipilimumab, Mesothelioma, Nivolumab.
- TrialCOSMIC-313
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.
- TrialA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P
Shares Ipilimumab, Nivolumab, Melanoma.
- TrialStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Shares Ipilimumab, Nivolumab, Metastatic cancer (cancer that has spread).
- TermSarcomatoid differentiation (RCC)
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.